Jiri Mayer

28PUBLICATIONS
332CO-AUTHORS
Molecular targetsHaematologyHaematological tumoursRespiratory diseasesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Mar 30, 2026
The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Maria Agustina Perusini, Katia Pagnano, Carolina Pavlovsky

|Mar 17, 2026
Chronic myeloid leukaemia: have basophils gone the way of the Dodo bird?

Lucia Turcsanyi, Xiao-Shuai Zhang, Milos Kudelka

|Feb 19, 2026
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.

Daniel Filip, Katerina Litzmanova, Androniki Michaelou

|Jan 19, 2026
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.

Delphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti

|Jan 06, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Stefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer

|Aug 04, 2025
Real-World Data From a Molecular Tumor Board-Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?

Michal Eid, Markéta Bednaříková, Jakub Vlažný

Pageof 5

Frequent Collaborators

5 joint publications

Barbora Weinbergerová

5 joint publications

Daniela Zackova

5 joint publications

Michael Doubek

4 joint publications

Ivana Jeziskova